Makoto Ujihara

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Performance of the Basal Aldosterone to Renin Ratio and of the Renin Stimulation Test by Furosemide and Upright Posture in Screening for Aldosterone-Producing Adenoma in Low Renin Hypertensives

Dai Hirohara, Kaoru Nomura, Takahiro Okamoto et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 61 citations

Medicine, Endocrinology, Cancer Screening +12

A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease

Tomoaki Tanaka, Fumitoshi Satoh, Makoto Ujihara et al. · Endocrine Journal · 2020 · 44 citations · Full text

Medicine, Endocrinology, Pharmacology +17